Amarin (AMRN) Hisse Özeti
Bir ilaç şirketi olan Amarin Corporation plc, Amerika Birleşik Devletleri'nde, Avrupa'da ve uluslararası alanda kardiyovasküler hastalıkların tedavisine yönelik terapötiklerin ticarileştirilmesi ve geliştirilmesiyle ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
AMRN Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Amarin Corporation plc Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$15.12 |
| 52 Haftanın En Yüksek Seviyesi | US$20.90 |
| 52 Haftanın En Düşük Seviyesi | US$12.96 |
| Beta | 0.80 |
| 1 Aylık Değişim | 1.54% |
| 3 Aylık Değişim | 4.42% |
| 1 Yıllık Değişim | -12.70% |
| 3 Yıllık Değişim | -38.03% |
| 5 Yıllık Değişim | -81.56% |
| Halka arzdan bu yana değişim | -99.87% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 22
AMRN: Guideline Endorsements Will Still Translate Into Weak Future Earnings
Analysts have kept their $12.50 price target on Amarin unchanged. They cited only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially alter their valuation view.Anlatı Güncellemesi • Jun 05
AMRN: Guideline Inclusion Will Still Lead To Persistent Revenue Pressure
Analysts kept their $12.50 price target for Amarin unchanged, citing only very small model tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially affect their overall valuation view. What's in the News Shareholders are scheduled to vote at the May 13, 2026 Annual General Meeting on adopting amended and restated articles of association, which would allow Amarin to send electronic notices of future Annual General Meetings via a website if approved.Anlatı Güncellemesi • May 21
AMRN: Guideline Support Will Not Prevent Future Revenue And Margin Pressure
Analysts have lifted their price target on Amarin stock by $0.50 to $12.50, citing updated assumptions around slightly lower expected revenue declines, a higher projected profit margin, a modestly reduced discount rate, and a lower future P/E multiple as the key drivers of the change. Analyst Commentary Recent commentary around Amarin’s updated price target highlights a mix of optimism on execution and ongoing caution on longer term growth and valuation risk.Recent updates
Anlatı Güncellemesi • Jun 22
AMRN: Guideline Endorsements Will Still Translate Into Weak Future Earnings
Analysts have kept their $12.50 price target on Amarin unchanged. They cited only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially alter their valuation view.Anlatı Güncellemesi • Jun 05
AMRN: Guideline Inclusion Will Still Lead To Persistent Revenue Pressure
Analysts kept their $12.50 price target for Amarin unchanged, citing only very small model tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially affect their overall valuation view. What's in the News Shareholders are scheduled to vote at the May 13, 2026 Annual General Meeting on adopting amended and restated articles of association, which would allow Amarin to send electronic notices of future Annual General Meetings via a website if approved.Anlatı Güncellemesi • May 21
AMRN: Guideline Support Will Not Prevent Future Revenue And Margin Pressure
Analysts have lifted their price target on Amarin stock by $0.50 to $12.50, citing updated assumptions around slightly lower expected revenue declines, a higher projected profit margin, a modestly reduced discount rate, and a lower future P/E multiple as the key drivers of the change. Analyst Commentary Recent commentary around Amarin’s updated price target highlights a mix of optimism on execution and ongoing caution on longer term growth and valuation risk.Anlatı Güncellemesi • Apr 24
AMRN: Guideline Endorsements And Execution Risks Will Limit Future Share Returns
Analysts have maintained their fair value estimate for Amarin at $12.00. They made only minor adjustments to assumptions such as the discount rate and future P/E, which resulted in no change to the updated price target.Anlatı Güncellemesi • Apr 08
AMRN: Guideline Support And Flat Earnings Outlook Will Restrain Future Upside
Narrative Update on Amarin Amarin's updated analyst price target holds steady at $12.00, as analysts point to only very small adjustments in discount rate, revenue growth assumptions, profit margin and future P/E that do not materially change their overall valuation view. Analyst Commentary Analysts covering Amarin are generally treating the current valuation as balanced, with the updated US$12.00 price target reflecting only modest tweaks to their core assumptions rather than a major shift in outlook.Anlatı Güncellemesi • Mar 25
AMRN: Guideline Tailwinds And Earnings Assumptions Will Limit Future Upside Potential
Amarin's updated analyst price target holds steady at $12.00, with analysts pointing to only marginal tweaks in the discount rate and long-term P/E assumptions as they refine their valuation framework rather than rethink the story. Analyst Commentary Analysts covering Amarin are keeping the updated US$12.00 target steady, framing recent tweaks as fine tuning of their models rather than a shift in the fundamental view on the company.Anlatı Güncellemesi • Mar 11
AMRN: Index Removal And Weaker Margins Will Restrict Future Upside Potential
Analysts have revised their price target on Amarin to $12.00, reflecting updated assumptions for revenue trends, profit margins, the discount rate, and a higher future P/E multiple in their models. Analyst Commentary Analysts revising their models for Amarin are focusing on how updated revenue and margin assumptions, along with the use of a higher P/E multiple, translate into the new US$12.00 price target.Anlatı Güncellemesi • Feb 25
AMRN: Index Removal And Execution Risks Will Limit Future Upside Potential
Analysts have modestly adjusted their price target on Amarin, keeping fair value around $12.00. Small tweaks to the discount rate and future P/E assumptions refine their view rather than signal a major shift in the story.Anlatı Güncellemesi • Feb 11
AMRN: Index Removal And Execution Risks Will Continue To Limit Upside
Analysts have adjusted their price target for Amarin to US$12.00. They attribute this move to slightly higher assumed discount rates, a modest tweak to long term revenue and margin expectations, and a small uplift in future P/E assumptions.Anlatı Güncellemesi • Jan 27
AMRN: Index Removal And Execution Risks Will Constrain Future Upside Potential
Analysts have reaffirmed Amarin's fair value at US$12.00 per share, citing only modest tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the stock. Analyst Commentary Analysts are largely using the reaffirmed US$12.00 fair value as a reference point to stress test their assumptions on growth, profitability and execution risk for Amarin, rather than to rethink the overall thesis.Anlatı Güncellemesi • Jan 12
AMRN: Index Removal And Weakening Revenue Outlook Will Constrain Future Upside Potential
Analysts have kept their fair value estimate for Amarin steady at US$12.00 per share, with only minor model tweaks to the discount rate, revenue trajectory and expected P/E that help to fine tune rather than shift their overall price target view. What's in the News Amarin issued revenue guidance for the fourth quarter of 2025, expecting net revenue of US$48 million to US$53 million, and for the full year 2025, expecting net revenue of US$212 million to US$217 million (corporate guidance).Analiz Makalesi • Dec 10
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Anlatı Güncellemesi • Dec 10
AMRN: Pricing And Competitive Pressures Will Likely Limit Future Upside Potential
Analysts have modestly lifted their price target on Amarin to $12.00 from $12.00. This reflects steady assumptions around long term discount rates, revenue growth, profit margins, and future earnings multiples despite a still cautious backdrop for the broader sector.Anlatı Güncellemesi • Nov 26
AMRN: Rising Competitive Pressures Will Likely Challenge Future Profit Margin Expansion
Amarin's analyst price target has increased from $11.00 to $12.00. This reflects analysts' expectations of improved revenue growth and a notably stronger profit margin outlook for the company.Analiz Makalesi • Oct 04
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a really impressive month, gaining 25% after a shaky period...Analiz Makalesi • Jun 12
Amarin Corporation plc (NASDAQ:AMRN) Shares Fly 27% But Investors Aren't Buying For Growth
Amarin Corporation plc ( NASDAQ:AMRN ) shares have continued their recent momentum with a 27% gain in the last month...Analiz Makalesi • Jun 12
We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jun 06
Amarin Is A Sell Despite The Large Cash Balance
Summary Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with operating expenses exceeding product revenues, and European launches have not offset U.S. declines. Amarin trades below its cash value, providing some margin of safety and potential M&A appeal, but ongoing cash burn will erode this over time. Given the lack of clear catalysts and persistent losses, I expect Amarin to generate negative returns unless strategic action occurs soon. Read the full article on Seeking Alpha
Yeni Anlatı • Apr 01
I Foresee 49 Approvals Driving European And Global Market Expansion
Expanded regulatory approvals and commercialization in 49 markets support future revenue growth, particularly through focused expansion in Europe and worldwide.Analiz Makalesi • Mar 15
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26%
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a horrible month, losing 26% after a relatively good period...Analiz Makalesi • Jan 24
Amarin Corporation plc (NASDAQ:AMRN) Held Back By Insufficient Growth Even After Shares Climb 39%
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Analiz Makalesi • Jan 03
Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analiz Makalesi • Oct 29
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1x Amarin Corporation plc ( NASDAQ:AMRN ) is definitely a...Analiz Makalesi • Aug 01
Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Amarin fair value estimate is US$0.53 Amarin's US$0.68 share...Analiz Makalesi • Jun 06
Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues
The Amarin Corporation plc ( NASDAQ:AMRN ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Apr 16
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Summary Amarin is going through a turbulent period with a strong contraction in revenue and margins. The EU and China markets seem too small to make significant changes, and the US market is suffering from margin erosion. The number of hedge funds that are investing in Amarin is reducing. My share price evaluation does not seem to offer positive returns on investment. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 12
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Amarin Corporation plc ( NASDAQ:AMRN ) shares have retraced a considerable 27% in the last month, reversing a fair...Seeking Alpha • Jan 15
Amarin: Sarissa Is Giving Me Hope Again
Summary Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, leading to its potential for greatness. The implementation of strategic proposals, a new CEO with relevant expertise, and higher than expected Q4 earnings are positive signs for Amarin's future. Read the full article on Seeking AlphaAnaliz Makalesi • Jan 03
Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Analiz Makalesi • Nov 19
Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Key Insights The projected fair value for Amarin is US$0.95 based on 2 Stage Free Cash Flow to Equity Current share...Hissedar Getirileri
| AMRN | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | -7.6% | 0.02% | 0.6% |
| 1Y | -12.7% | 36.1% | 19.5% |
Getiri vs. Endüstri: AMRN geçen yıl % 36.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: AMRN geçen yıl % 19.5 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| AMRN volatility | |
|---|---|
| AMRN Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: AMRN son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: AMRN 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1989 | 80 | Aaron Berg | www.amarincorp.com |
Bir ilaç şirketi olan Amarin Corporation plc, Amerika Birleşik Devletleri, Avrupa ve uluslararası alanda kardiyovasküler hastalıkların tedavisi için terapötiklerin ticarileştirilmesi ve geliştirilmesiyle ilgilenmektedir. Şiddetli hipertrigliseridemisi olan yetişkin hastalarda trigliserit seviyelerini düşürmek için diyete ek olarak kullanılan reçeteli bir omega-3 yağ asidi ürünü olan VASCEPA'yı sunmaktadır. Şirket ürünlerini esas olarak toptancılar, seçilmiş bölgesel toptancılar ve perakende ve posta siparişi eczane sağlayıcıları aracılığıyla satmaktadır.
Amarin Corporation plc Temel Bilgiler Özeti
| AMRN temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$318.10m |
| Kazançlar(TTM) | -US$33.61m |
| Gelir(TTM) | US$216.76m |
1.5x
P/S Oranı-9.4x
F/K OranıAMRN aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| AMRN gelir tablosu (TTM) | |
|---|---|
| Gelir | US$216.76m |
| Gelir Maliyeti | US$103.25m |
| Brüt Kâr | US$113.51m |
| Diğer Giderler | US$147.12m |
| Kazançlar | -US$33.61m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.60 |
| Brüt Marj | 52.36% |
| Net Kâr Marjı | -15.51% |
| Borç/Özkaynak Oranı | 0% |
AMRN uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/09 11:47 |
| Gün Sonu Hisse Fiyatı | 2026/07/09 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Amarin Corporation plc 19 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Andrew Fein | Chardan Capital Markets, LLC |
| John Boris | Citigroup Inc |